Identification of the functional impact of mutated and altered genes in cancer is critical for implementing precision oncology and drug repurposing.In recent years,the emergence of multiomics data from large,well-characterized patient cohorts has provided us with an unprecedented opportunity to address this problem.In this study,we investigated survival-associated genes across 26 cancer types and found that these genes tended to be hub genes and had higher K-core values in biological networks.Moreover,the genes associated with adverse outcomes were mainly enriched in pathways related to genetic information processing and.cellular processes,while the genes with favorable outcomes were enriched in metabolism and immune regulation pathways.We proposed using the number of survival-related neighbors to assess the impact of mutations.In addition,by integrating other databases including the Human Protein Atlas and the DrugBank database,we predicted novel targets and anticancer drugs using the drug repurposing strategy.Our results illustrated the significance of multidimensional analysis of clinical data in important gene identification and drug development.